1Pasquini L,Petronelli A,Petrucci E. Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhi-bitors[J].International Journal of Oncology,2010.707-713.
2Russo A,Bronte G,Fulfaro F. Bortezomib:a new proapop-totic agent in cancer treatment[J].Current Cancer Drug Targets,2010.55-67.
3Seki N,Toh U,Sayers TJ. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways[J].Molecular Cancer Therapeutics,2010.1842-1851.
4Tamura D,Arao T,Tanaka K. Bortezomib potentially inhi -bits cellular growth of vascular endothelial cells through suppres -sion of G2/M transition[J].Cancer Science,2010.1403-1408.
5Blanco B,Perez-Simon JA,Sanchez-Abarca LI. Bortezomib induces selective depletion of alloreactive T lymphocytes and de-creases the production of Th1 cytokines[J].Blood,2006.3575-3583.
4Jagannath S, Barlogie B, Berenson J ,et al.A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma[J]. Br J Haematol, 2004,127 (2) : 165-72.
5Fermand JP, Ravaud P, Chevret S,et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma~ up-front or rescue treatment Results of a multicenter sequential randomized clinical trial[J]. Blood, 1998, 92 (9): 3131-3136.
6Morabito F, Gentile M, Mazzone C, et al. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by borte zomib- thalidomide maintenance (VMPT-VT) versus bortezomib- melphalan-prednisone (VMP) [J]. Blood, 2011,118 (22) : 5759- 5766.
